EUVIMEDEUVIMED entdecken
Crossref

MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study

Eugene Han iD, Ho Soo Chun iD, Yong-Ho Lee, Jae Seung Lee iD, Hye Won Lee iD, Beom Kyung Kim iD, Jun Yong Park, Do Young Kim iD, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Sang Hoon Ahn iD und 1 weitere

Journal of Gastroenterology and Hepatology · 2023

DOI: 10.1111/jgh.16261 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2023. Verfasst von Eugene Han und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Cardiovascular Diseases, Sarcopenia. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Ministry of Education, Ministry of Science and ICT, South Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Clinical features of non‐alcoholic fatty liver disease (NAFLD), but not fulfilling the diagnostic criteria of metabolic dysfunction‐associated fatty liver disease (MAFLD), remain unclear. We investigated the risk of sarcopenia and cardiovascular disease (CVD) in MAFLD and non‐metabolic risk (MR) NAFLD.

Methods

Subjects were selected from the Korean National Health and Nutrition Examination Surveys 2008–2011. Liver steatosis was assessed using fatty liver index. Significant liver fibrosis was defined using fibrosis‐4 index, categorized by age cut‐offs. Sarcopenia was defined as the lowest quintile sarcopenia index. Atherosclerotic CVD (ASCVD) risk score > 10% was defined as high probability.

Results

A total of 7248 subjects had fatty liver (137 with non‐MR NAFLD, 1752 with MAFLD/non‐NAFLD, and 5359 with overlapping MAFLD and NAFLD). In non‐MR NAFLD group 28 (20.4%) had significant fibrosis. The risk of sarcopenia (adjusted odds ratio [aOR] = 2.71, 95% confidence index [CI] = 1.27–5.78) and high probability of ASCVD (aOR = 2.79, 95% CI = 1.23–6.35) was significantly higher in MAFLD/non‐NAFLD group than in non‐MR NAFLD group (all P < 0.05). The risk of sarcopenia and high probability of ASCVD was similar between subjects with and without significant fibrosis in non‐MR NAFLD group (all P > 0.05). However, the risk was significantly higher in MAFLD group than in non‐MR NAFLD group (aOR = 3.38 for sarcopenia and 3.73 for ASCVD; all P < 0.05).

Conclusions

The risks of sarcopenia and CVD were significantly higher in MAFLD group but did not differ according to fibrotic burden in non‐MR NAFLD group. The MAFLD criteria might be better for identifying high‐risk fatty liver disease than the NAFLD criteria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseCardiovascular DiseasesSarcopeniaHumansRisk FactorsHeart Disease Risk Factors

Stichwörter der Autor:innen

Cardiovascular diseaseLiver fibrosisMetabolic dysfunction-associated fatty liver diseaseNon-alcoholic fatty liver diseaseSarcopenia

Autor:innen und Institutionen

  • Department of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea.
  • Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, South Korea.
  • Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
  • Institute of Endocrine Research, Yonsei University College of Medicine, Seoul, South Korea.
  • Yonsei Liver Center, Severance Hospital, Seoul, South Korea.

ORCID-Profile: Eugene Han, Ho Soo Chun, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Do Young Kim, Sang Hoon Ahn, Seung Up Kim

Förderung

  • Ministry of Education
  • Ministry of Science and ICT, South Korea

Zitieren

APA

Han, E., Chun, H. S., Lee, Y. H., Lee, J. S., Lee, H. W., Kim, B. K., Park, J. Y., Kim, D. Y., Lee, B. W., Kang, E. S., Cha, B. S., Ahn, S. H., & Kim, S. U. (2023). MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16261

Vancouver

Han E, Chun HS, Lee YH, Lee JS, Lee HW, Kim BK, et al. MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study. Journal of Gastroenterology and Hepatology. 2023. doi:10.1111/jgh.16261

BibTeX
@article{Han2023,
  author = {Han, Eugene and Chun, Ho Soo and Lee, Yong-Ho and Lee, Jae Seung and Lee, Hye Won and Kim, Beom Kyung and Park, Jun Yong and Kim, Do Young and Lee, Byung-Wan and Kang, Eun Seok and Cha, Bong-Soo and Ahn, Sang Hoon and Kim, Seung Up},
  title = {MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2023},
  doi = {10.1111/jgh.16261}
}
Kostenlos starten →